SEC Form 4 · accession 0001609351-18-000030
Spark Therapeutics, Inc. · ONCE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Furey
Officer — Chief Operating Officer
Period of report
Apr 12, 2018
Accepted (ET)
Apr 16, 2018 · 5:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609351
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 12, 2018 | M | 20,000 | $49.74 | A | 20,000 | D | |
| Common StockF1 | Apr 12, 2018 | S | 20,000 | $77.51 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $49.74 | Apr 12, 2018 | M | 20,000 | D | — | Nov 30, 2026 | Common Stock | 20,000 | 140,000 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.50 to $77.56, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.
- F225% vests December 1, 2017 and the remainder vests in equal quarterly installments over the following three years following December 1, 2017.